Gefitinib for oesophageal cancer: a cog in need of a wheel?
Mené sur 450 patients atteints d'un cancer de l'œsophage de stade avancé, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du gefitinib en traitement de deuxième ligne
Oesophageal cancer remains a deadly cancer, with a 5-year survival of 13%. Worldwide, squamous-cell carcinoma predominates. However, in western populations squamous tumours are now rarer than adenocarcinoma, because of increasing obesity and reflux disease. After failure of platinum and fluoropyrimidine, second-line chemotherapy provides a survival advantage in oesophagogastric adenocarcinoma, but evidence for second-line therapy in squamous cancer is sparse.
The Lancet Oncology , commentaire, 2013